BDC-4182
Gastric Cancer, Gastroesophageal Junction Cancer (Claudin 18.2+)
Phase 1Active, Enrollment Open
Key Facts
Indication
Gastric Cancer, Gastroesophageal Junction Cancer (Claudin 18.2+)
Phase
Phase 1
Status
Active, Enrollment Open
Company
About Bolt Biotherapeutics
Bolt Biotherapeutics is developing targeted immunotherapies based on its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform, which aims to harness the innate immune system to fight cancer. Founded in 2015 on foundational research from Stanford University, the company's strategy centers on advancing its lead clinical asset, BDC-4182, and leveraging collaborations to expand its pipeline. As a pre-revenue public company, Bolt faces the critical challenge of generating compelling clinical proof-of-concept data to validate its platform and attract further investment or partnership capital in a competitive oncology landscape.
View full company profile